Get started
Author

Kunihiro Yoshisue

Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
2000 · K Ikeda, K Yoshisue, et al. · PubMed · 167
The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling
2008 · Motohiro Kato, Yoshihisa Shitara, et al. · Pharmaceutical Research · 113
Simultaneous Expression of Guinea Pig UDP-Glucuronosyltransferase 2B21 and 2B22 in COS-7 Cells enhances UDP-Glucuronosyltransferase 2B21-Catalyzed Morphine-6-Glucuronide Formation
2001 · Yuji Ishii, Aya Miyoshi, et al. · Molecular Pharmacology · 70
Tissue Distribution and Biotransformation of Potassium Oxonate after Oral Administration of a Novel Antitumor Agent (Drug Combination of Tegafur, 5-Chloro-2,4-dihydroxypyridine, and Potassium Oxonate) to Rats
2000 · Kunihiro Yoshisue, Hirotoshi Masuda, et al. · Drug Metabolism and Disposition · 35
First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers
2014 · Kaku Saito, Hirotaka Nagashima, et al. · Cancer Chemotherapy and Pharmacology · 33
TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
2018 · Wakako Yano, Tatsushi Yokogawa, et al. · Molecular Cancer Therapeutics · 30
Effects of 5-Fluorouracil on the Drug-Metabolizing Enzymes of the Small Intestine and the Consequent Drug Interaction with Nifedipine in Rats
2001 · Kunihiro Yoshisue, Sekio Nagayama, et al. · Journal of Pharmacology and Experimental Therapeutics · 28
Purification of a Phenobarbital-Inducible UDP-Glucuronosyltransferase Isoform from Dog Liver Which Catalyzes Morphine and Testosterone Glucuronidation
1996 · Kazuta Oguri, Akiko Kurogi, et al. · Archives of Biochemistry and Biophysics · 28
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats
2000 · Kunihiro Yoshisue, Kazue Hironaga, et al. · Cancer Chemotherapy and Pharmacology · 26
Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse
2015 · Fumiaki Yamashita, Ikumi Komoto, et al. · Cancer Chemotherapy and Pharmacology · 24
Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells
2015 · Koichi Takahashi, Kunihiro Yoshisue, et al. · Journal of Pharmaceutical Sciences · 18
PDF
Effect of CYP2A6 Genetic Polymorphism on the Metabolic Conversion of Tegafur to 5-Fluorouracil and Its Enantioselectivity
2014 · Ikuo Yamamiya, Kunihiro Yoshisue, et al. · Drug Metabolism and Disposition · 17
Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine
2017 · Koichi Takahashi, Kunihiro Yoshisue, et al. · Biopharmaceutics & Drug Disposition · 13
Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats
2009 · Kunihiro Yoshisue, Shohei Kanie, et al. · Journal of Pharmacy and Pharmacology · 13
Pharmacokinetics and Biological Fate of 3-(2,2,2-Trimethylhydrazinium)Propionate Dihydrate (MET-88), a Novel Cardioprotective Agent, in Rats
2000 · Kunihiro Yoshisue, Yoshio Yamamoto, et al. · Drug Metabolism and Disposition · 13
Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial.
2015 · James M. Cleary, Robert J. Mayer, et al. · Journal of Clinical Oncology · 10
Formation Pathways of γ-Butyrolactone from the Furan Ring of Tegafur during Its Conversion to 5-Fluorouracil
2010 · Ikuo Yamamiya, Kunihiro Yoshisue, et al. · Drug Metabolism and Disposition · 7
A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114
2021 · Hikari Araki, Toru Takenaka, et al. · CPT Pharmacometrics & Systems Pharmacology · 5
Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients
2019 · Hirofumi Yasui, Takeshi Kawakami, et al. · International Journal of Clinical Oncology · 5
PDF
65 TAS-114 Enhances S-1 Activity in Vivo When Used in Combination
2012 · T. Yokogawa, T. Wakasa, et al. · European Journal of Cancer · 5
Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluorothymidine, a Novel Antitumor Nucleoside, in Rats
2011 · Takashige Okayama, Kunihiro Yoshisue, et al. · Journal of Pharmacology and Experimental Therapeutics · 5
Abstract CT014: A large phase I study of TAS-114 in combination with S-1 in patients with advanced solid tumors
2018 · Angelica Fasolo, Takekazu Aoyama, et al. · Cancer Research · 4
Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer
2016 · Takayuki Yoshino, Ichinosuke Hyodo, et al. · Cancer Chemotherapy and Pharmacology · 4
Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys
2014 · Ikuo Yamamiya, Kunihiro Yoshisue, et al. · Journal of Pharmacy and Pharmacology · 4
Population pharmacokinetic (PPK) analysis for 5-FU, tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo) in the eight clinical studies of S-1 in Western patients with advanced solid tumors.
2011 · K. Yoshida, K. Ikeda, et al. · Journal of Clinical Oncology · 4
Works count: 55
Citation count: 689
H-index: 13
I10-index: 16
Year
Topic
Type